Movement Alert｜CANSINOBIO Rises 5.13% in Regular Trading, Equity Incentive Reserved Grant Lands Signaling Management Confidence

Market Focus09-17

On September 17, CANSINOBIO rose 5.13% in regular trading, trading at 26.56 HKD/share, with turnover of approximately 78.05 million HKD.

On the news front, the company announced on September 16 that its board resolved to grant a total of 287,400 restricted A-shares to 19 eligible employees under the reserved portion of its A-share restricted stock incentive plan, at a grant price of RMB 41.20 per share, representing 0.1163% of total share capital. The completion of this reserved grant is viewed as a signal of management confidence in the company's development trajectory.

On the fundamental side, CANSINOBIO reported H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while net loss attributable to shareholders narrowed sharply to RMB 720,800, representing a 94.65% improvement. Most notably, overseas revenue surged 4,724.19% year-over-year to RMB 1.52 billion, driven by a composite internationalization model encompassing finished vaccine sales, intermediate product supply, technology transfer, and joint overseas clinical development. The broader biotech sector also provided a supportive backdrop, with peers including AKESO and BEONE MEDICINES posting gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185541846?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185541846","market":"hk","top_or_hot":-1,"title":"Movement Alert｜CANSINOBIO Rises 5.13% in Regular Trading, Equity Incentive Reserved Grant Lands Signaling Management Confidence","media":"Market Focus","content":"<p><p>On September 17, CANSINOBIO rose 5.13% in regular trading, trading at 26.56 HKD/share, with turnover of approximately 78.05 million HKD.</p><p>On the news front, the company announced on September 16 that its board resolved to grant a total of 287,400 restricted A-shares to 19 eligible employees under the reserved portion of its A-share restricted stock incentive plan, at a grant price of RMB 41.20 per share, representing 0.1163% of total share capital. The completion of this reserved grant is viewed as a signal of management confidence in the company's development trajectory.</p><p>On the fundamental side, CANSINOBIO reported H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while net loss attributable to shareholders narrowed sharply to RMB 720,800, representing a 94.65% improvement. Most notably, overseas revenue surged 4,724.19% year-over-year to RMB 1.52 billion, driven by a composite internationalization model encompassing finished vaccine sales, intermediate product supply, technology transfer, and joint overseas clinical development. The broader biotech sector also provided a supportive backdrop, with peers including AKESO and BEONE MEDICINES posting gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CANSINOBIO Rises 5.13% in Regular Trading, Equity Incentive Reserved Grant Lands Signaling Management Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CANSINOBIO Rises 5.13% in Regular Trading, Equity Incentive Reserved Grant Lands Signaling Management Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-17 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 17, CANSINOBIO rose 5.13% in regular trading, trading at 26.56 HKD/share, with turnover of approximately 78.05 million HKD.</p><p>On the news front, the company announced on September 16 that its board resolved to grant a total of 287,400 restricted A-shares to 19 eligible employees under the reserved portion of its A-share restricted stock incentive plan, at a grant price of RMB 41.20 per share, representing 0.1163% of total share capital. The completion of this reserved grant is viewed as a signal of management confidence in the company's development trajectory.</p><p>On the fundamental side, CANSINOBIO reported H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while net loss attributable to shareholders narrowed sharply to RMB 720,800, representing a 94.65% improvement. Most notably, overseas revenue surged 4,724.19% year-over-year to RMB 1.52 billion, driven by a composite internationalization model encompassing finished vaccine sales, intermediate product supply, technology transfer, and joint overseas clinical development. The broader biotech sector also provided a supportive backdrop, with peers including AKESO and BEONE MEDICINES posting gains.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1185541846","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185541846","pubTimestamp":1789612225,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 17, CANSINOBIO rose 5.13% in regular trading, trading at 26.56 HKD/share, with turnover of approximately 78.05 million HKD.On the news front, the company announced on September 16 that...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"走势提醒|康希诺生物常规交易上涨5.13%，股权激励预留赠地显示管理层信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"On September 17, CANSINOBIO rose 5.13% in regular trading, trading at 26.56 HKD/share, with turnover of approximately 78.05 million HKD.On the news front, the company announced on September 16 that its board resolved to grant a total of 287,400 restricted A-shares to 19 eligible employees under the reserved portion of its A-share restricted stock incentive plan, at a grant price of RMB 41.20 per share, representing 0.1163% of total share capital. The completion of this reserved grant is viewed as a signal of management confidence in the company's development trajectory.On the fundamental side, CANSINOBIO reported H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while net loss attributable to shareholders narrowed sharply to RMB 720,800, representing a 94.65% improvement. Most notably, overseas revenue surged 4,724.19% year-over-year to RMB 1.52 billion, driven by a composite internationalization model encompassing finished vaccine sales, intermediate product supply, technology transfer, and joint overseas clinical development. The broader biotech sector also provided a supportive backdrop, with peers including AKESO and BEONE MEDICINES posting gains.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185541846","isCrawlerRequest":true}